A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function
Journal of Cystic Fibrosis · 2025-01 · 24 (1) · 164-174
DOI: 10.1016/j.jcf.2024.10.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-01. Verfasst von Margaret Michicich und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, United States. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
BACKGROUND: People with cystic fibrosis carrying two nonsense alleles lack CFTR-specific treatment. Growing evidence supports the hypothesis that nonsense mutation identity affects therapeutic response, calling for mutation-specific CF models. We describe a novel W1282X mouse model and compare it to an existing G542X mouse. METHODS: The W1282X mouse was created using CRISPR/Cas9 to edit mouse Cftr. In this model, Cftr transcription was assessed using qRT-PCR and CFTR function was measured in the airway by nasal potential difference and in the intestine by short circuit current. Growth, survival, and intestinal motility were examined as well. Correction of W1282X CFTR was assessed pharmacologically and by gene-editing using a forskolin-induced swelling (FIS) assay in small intestine-derived organoids. RESULTS: Homozygous W1282X mice demonstrate decreased Cftr mRNA, little to no CFTR function, and reduced survival, growth, and intestinal motility. W1282X organoids treated with various combinations of pharmacologic correctors display a significantly different amount of CFTR function than that of organoids from G542X mice. Successful gene editing of W1282X to wildtype sequence in intestinal organoids was achieved leading to restoration of CFTR function. CONCLUSIONS: The W1282X mouse model recapitulates common human manifestations of CF similar to other CFTR null mice. Despite the similarities between the congenic W1282X and G542X models, they differ meaningfully in their response to identical pharmacological treatments. This heterogeneity highlights the importance of studying therapeutics across genotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, United States.
- Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, United States. Electronic address: craig.hodges@case.edu.
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- Cystic Fibrosis Foundation
- National Institutes of Health
Zitieren
APA
Michicich, M., Traylor, Z., McCoy, C., Valerio, D. M., Wilson, A., Schneider, M., Davis, S., Barabas, A., Mann, R. J., LePage, D. F., Jiang, W., Drumm, M. L., Kelley, T. J., Conlon, R. A., & Hodges, C. A. (2025). A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function. Journal of Cystic Fibrosis, 24(1), 164-174. https://doi.org/10.1016/j.jcf.2024.10.008
Vancouver
Michicich M, Traylor Z, McCoy C, Valerio DM, Wilson A, Schneider M, et al. A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function. Journal of Cystic Fibrosis. 2025;24(1):164-174. doi:10.1016/j.jcf.2024.10.008
BibTeX
@article{Michicich2025,
author = {Michicich, Margaret and Traylor, Zachary and McCoy, Caitlan and Valerio, Dana M and Wilson, Alma and Schneider, Molly and Davis, Sakeena and Barabas, Amanda and Mann, Rachel J and LePage, David F and Jiang, Weihong and Drumm, Mitchell L and Kelley, Thomas J and Conlon, Ronald A and Hodges, Craig A},
title = {A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {1},
pages = {164--174},
doi = {10.1016/j.jcf.2024.10.008}
}
EUVIMED